Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
18 May 2018
E-001930/2018
Answer given by Mr Moedas on behalf of the Commission

1. The Commission is aware of the research referred to by the Honourable Member(1). The Commission does not hold data specifically on the effectiveness of the combination of a CpG(2) oligodeoxynucleotide and an antibody against OX40(3). However, research on similar T-cell checkpoint inhibitors is being supported through Horizon 2020, the EU Framework Programme for Research and Innovation (2014-2020)(4), for instance in the ‘Immunostimulatory Agonist antibodies for Cancer Therapy’ (IACT) and ‘Blocking Inhibition of T-cell Co-stimulation for Anti-tumour Therapy’ (BITCAT) projects(5), which are examining the potential of this approach for treating cancer.

2. The Horizon 2020 2018-2020 Work Programme offers opportunities to conduct research on potential benefits and risks of immunostimulating agents(6)-(7). Full information on funding opportunities under Horizon 2020 is available on the Research and Innovation Participant Portal(8)-(9) and on the ‘Access to EU Finance’ Europa website(10).

(1)https://www.ncbi.nlm.nih.gov/pubmed/29386357
(2)Short DNA molecule containing cytosine triphosphate deoxynucleotide followed by a guanine triphosphate deoxynucleotide.
(3)A molecule that can be found on the surface of certain white blood cells of the immune system.
(4)https://ec.europa.eu/programmes/horizon2020/
(5)IACT: https://cordis.europa.eu/project/rcn/110142_en.html BITCAT: https://cordis.europa.eu/project/rcn/206132_en.html
(6)Through the ‘Health, demographic change and wellbeing’ societal challenge, as well as the ‘Excellent science’ and ‘Industrial leadership’ pillars. http://ec.europa.eu/programmes/horizon2020/en/h2020-section/health-demographic-change-and-wellbeing
(7)Research and Innovation Participant Portal: http://ec.europa.eu/research/participants/portal/desktop/en/opportunities/index.html
(8)http://ec.europa.eu/research/participants/portal/desktop/en/home.html
(9)http://ec.europa.eu/research/participants/portal/desktop/en/opportunities/h2020/index.html
(10)http://europa.eu/youreurope/business/funding-grants/access-to-finance/index_en.htm

Last updated: 18 May 2018Legal notice